AstraZeneca Pharma India PAT at Rs 10.24 crores
Board declares interim dividend of Rs 2 per equity share
Board declares interim dividend of Rs 2 per equity share
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
Advances deployment of mRNA technology across vaccines and therapeutics development
He will be stationed at the company HQ in Bengaluru, India
Releasing it, Union Minister Jitendra Singh said India needs its database for Indian research and solutions.
Deal for 100 million doses with additional 100 million through 2023
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
The company has received a certificate of Good Manufacturing Practice compliance from the Medicines & Healthcare products Regulatory Agency (MHRA) UK
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
The centralized marketing authorization granted by the EC is valid in all EU Member
The partnership is a significant step in delivering advanced cancer therapies to patients.
Subscribe To Our Newsletter & Stay Updated